Form 8-K - Current report:
SEC Accession No. 0001193125-25-240766
Filing Date
2025-10-16
Accepted
2025-10-16 06:01:52
Documents
12
Period of Report
2025-10-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d40644d8k.htm   iXBRL 8-K 23260
  Complete submission text file 0001193125-25-240766.txt   136346

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA dvax-20251015.xsd EX-101.SCH 2849
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE dvax-20251015_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dvax-20251015_pre.xml EX-101.PRE 11260
15 EXTRACTED XBRL INSTANCE DOCUMENT d40644d8k_htm.xml XML 3667
Mailing Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 251396326
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)